Cargando…

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice

Availability of novel hormonal therapies as well as docetaxel and cabazitaxel treatment for metastatic castration-resistant prostate cancer (CRPC) has changed the outlook for this group of patients with improvements in progression-free survival and overall survival. Physicians often diagnose the pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizokami, Atsushi, Izumi, Kouji, Konaka, Hiroyuki, Kitagawa, Yasuhide, Kadono, Yoshifumi, Narimoto, Kazutaka, Nohara, Takahiro, Bahl, Amit K, Namiki, Mikio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312209/
https://www.ncbi.nlm.nih.gov/pubmed/27270339
http://dx.doi.org/10.4103/1008-682X.179159
_version_ 1782508161491533824
author Mizokami, Atsushi
Izumi, Kouji
Konaka, Hiroyuki
Kitagawa, Yasuhide
Kadono, Yoshifumi
Narimoto, Kazutaka
Nohara, Takahiro
Bahl, Amit K
Namiki, Mikio
author_facet Mizokami, Atsushi
Izumi, Kouji
Konaka, Hiroyuki
Kitagawa, Yasuhide
Kadono, Yoshifumi
Narimoto, Kazutaka
Nohara, Takahiro
Bahl, Amit K
Namiki, Mikio
author_sort Mizokami, Atsushi
collection PubMed
description Availability of novel hormonal therapies as well as docetaxel and cabazitaxel treatment for metastatic castration-resistant prostate cancer (CRPC) has changed the outlook for this group of patients with improvements in progression-free survival and overall survival. Physicians often diagnose the progression of prostate cancer using serum prostate-specific antigen (PSA). However, serum PSA is not always correlated with the clinical status in CRPC. To evaluate the PSA dynamics with greater precision, understanding of the control of PSA and of the mechanisms of development of CRPC is needed. Moreover, it is necessary to use new hormonal therapies with an appropriate timing to optimally improve the prognosis and the QOL of the patients. In the present review, we ascertain the PSA dynamics and the mechanisms of the development of CRPC to assist in optimal utilization of the new treatments for mCRPC.
format Online
Article
Text
id pubmed-5312209
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-53122092017-03-01 Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice Mizokami, Atsushi Izumi, Kouji Konaka, Hiroyuki Kitagawa, Yasuhide Kadono, Yoshifumi Narimoto, Kazutaka Nohara, Takahiro Bahl, Amit K Namiki, Mikio Asian J Androl Review Availability of novel hormonal therapies as well as docetaxel and cabazitaxel treatment for metastatic castration-resistant prostate cancer (CRPC) has changed the outlook for this group of patients with improvements in progression-free survival and overall survival. Physicians often diagnose the progression of prostate cancer using serum prostate-specific antigen (PSA). However, serum PSA is not always correlated with the clinical status in CRPC. To evaluate the PSA dynamics with greater precision, understanding of the control of PSA and of the mechanisms of development of CRPC is needed. Moreover, it is necessary to use new hormonal therapies with an appropriate timing to optimally improve the prognosis and the QOL of the patients. In the present review, we ascertain the PSA dynamics and the mechanisms of the development of CRPC to assist in optimal utilization of the new treatments for mCRPC. Medknow Publications & Media Pvt Ltd 2017 2016-06-03 /pmc/articles/PMC5312209/ /pubmed/27270339 http://dx.doi.org/10.4103/1008-682X.179159 Text en Copyright: © 2017 Asian Journal of Andrology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Review
Mizokami, Atsushi
Izumi, Kouji
Konaka, Hiroyuki
Kitagawa, Yasuhide
Kadono, Yoshifumi
Narimoto, Kazutaka
Nohara, Takahiro
Bahl, Amit K
Namiki, Mikio
Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
title Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
title_full Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
title_fullStr Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
title_full_unstemmed Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
title_short Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
title_sort understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312209/
https://www.ncbi.nlm.nih.gov/pubmed/27270339
http://dx.doi.org/10.4103/1008-682X.179159
work_keys_str_mv AT mizokamiatsushi understandingprostatespecificantigendynamicsinmonitoringmetastaticcastrationresistantprostatecancerimplicationsforclinicalpractice
AT izumikouji understandingprostatespecificantigendynamicsinmonitoringmetastaticcastrationresistantprostatecancerimplicationsforclinicalpractice
AT konakahiroyuki understandingprostatespecificantigendynamicsinmonitoringmetastaticcastrationresistantprostatecancerimplicationsforclinicalpractice
AT kitagawayasuhide understandingprostatespecificantigendynamicsinmonitoringmetastaticcastrationresistantprostatecancerimplicationsforclinicalpractice
AT kadonoyoshifumi understandingprostatespecificantigendynamicsinmonitoringmetastaticcastrationresistantprostatecancerimplicationsforclinicalpractice
AT narimotokazutaka understandingprostatespecificantigendynamicsinmonitoringmetastaticcastrationresistantprostatecancerimplicationsforclinicalpractice
AT noharatakahiro understandingprostatespecificantigendynamicsinmonitoringmetastaticcastrationresistantprostatecancerimplicationsforclinicalpractice
AT bahlamitk understandingprostatespecificantigendynamicsinmonitoringmetastaticcastrationresistantprostatecancerimplicationsforclinicalpractice
AT namikimikio understandingprostatespecificantigendynamicsinmonitoringmetastaticcastrationresistantprostatecancerimplicationsforclinicalpractice